Parameter | Total | PDAC | DBDAC | AMPAC | DUOAC | p | |
---|---|---|---|---|---|---|---|
N | 198 | 126 | 23 | 40 | 9 | - | |
Male : female | 102:96 | 63:63 | 14:9 | 22:18 | 3:6 | 0.511 | |
Age | 67 (30–89) | 67 (30–89) | 69 (49–83) | 65 (36–84) | 66 (46–78) | 0.137 | |
Distant metastasis (M1) | 7 / 4% | 4 / 3% | 0 / 0% | 2 / 5% | 1 / 11% | 0.448 | |
Neoadjuvant therapy | 14 / 7% | 13 / 10% | 0 / 0% | 1 / 3% | 0 / 0% | 0.126 | |
Resection | PPPD | 163 | 103 | 19 | 34 | 7 | 0.803 |
Whipple | 23 | 14 | 2 | 5 | 2 | ||
total PE | 12 | 9 | 2 | 1 | 0 | ||
PVR | 62 / 31% | 53 /42% | 6 / 26% | 2 / 5% | 1 / 11% | 0.000 | |
Perioperative mortality | 7 / 4% | 5 / 4% | 2 / 9% | 0 / 0% | 0 / 0% | 0.300 | |
Tumor size (mm) | 25 (1–320) | 27 (1–80) | 15 (8–25) | 20 (2–320) | 40 (22–60) | 0.000 | |
Grade G3/4 | 72 / 37% | 48 / 39% | 8 / 35% | 12 / 31% | 4 / 44% | 0.785 | |
Stage T3/4 | 155 / 78% | 109 / 87% | 18 / 78% | 21 / 53% | 7 / 78% | 0.000 | |
Stage N1/2 | 132 / 67% | 89 / 71% | 14 / 61% | 24 / 60% | 5 / 56% | 0.468 | |
Lymph node ratio (LNR) | .09 (0 - .86) | .10 (0 - .86) | .08 (0 - .72) | .07 (0 - .71) | .10 (0 - .28) | 0.694 | |
Lymphangiosis (L1) | 87 / 44% | 60 / 48% | 5 / 22% | 19 / 48% | 3 / 33% | 0.116 | |
Hemangiosis (V1) | 29 / 15% | 22 / 18% | 3 / 13% | 2 / 5% | 2 / 22% | 0.237 | |
Perineural invasion (Pn1) | 113 / 57% | 88 / 70% | 12 / 52% | 13 / 33% | 0 / 0% | 0.000 | |
Associated precursor | Adenoma | 20 / 10% | 1 / 1% | 4 / 17% | 12 / 30% | 3 / 33% | 0.000 |
IPMN | 11 / 6% | 11 / 9% | 0 / 0% | 0 / 0% | 0 / 0% | 0.084 | |
Positive resection margin | 51 / 26% | 41 / 33% | 5 / 22% | 3 / 8% | 2 / 22% | 0.017 | |
Subtype | |||||||
INT | 39 / 20% | 11 / 9% | 5 / 22% | 18 / 45% | 5 / 56% | 0.000 | |
MIX | 12 / 6% | 8 / 6% | 2 / 9% | 2 / 5% | 0 / 0% | ||
PB | 118 / 16% | 89 / 71% | 12 / 52% | 15 / 38% | 2 / 22% | ||
OTH | 6 / 3% | 5 / 4% | 0 / 0% | 0 / 0% | 1 / 11% | ||
POOR | 23 / 12% | 13 / 10% | 4 / 17% | 5 / 13% | 1 / 11% | ||
Immunohistochemical Markers | |||||||
% CK7+ | 90 (0–100) | 90 (0–100) | 95 (0–100) | 80 (0–100) | 0 (0–60) | 0.000 | |
% CK20+ | 0 (0–100) | 0 (0–100) | 0 (0–100) | 10 (0–100) | 70 (10–100) | 0.000 | |
% nuclear CDX2+ | 10 (0–100) | 0 (0–100) | 0 (0–100) | 50 (0–100) | 95 (60–100) | 0.000 |